» Articles » PMID: 35493838

Up to What Extent Does Dravet Syndrome Benefit From Neurostimulation Techniques?

Overview
Journal Front Neurol
Specialty Neurology
Date 2022 May 2
PMID 35493838
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dravet syndrome (DS) is a refractory developmental and epileptic encephalopathy (EE) with a variety of comorbidities, including cognitive impairment, autism-like behavior, speech dysfunction, and ataxia, which can seriously affect the quality of life of patients and impose a great burden on society and their families. Currently, the pharmacological therapy is patient dependent and may work or not. Neuromodulation techniques, including vagus nerve stimulation (VNS), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), responsive neurostimulation (RNS), and chronic subthreshold cortical stimulation (CSCS), have become common adjuvant therapies for neurological diseases, but their efficacy in the treatment of DS is unknown.

Methods: We searched Web of Science, PubMed, and SpringerLink for all published cases related to the neuromodulation techniques of DS until January 15, 2022. The systematic review was supplemented with relevant articles from the references. The results reported by each study were summarized narratively.

Results: The Web of science, PubMed and SpringerLink search yielded 258 items. A total of 16 studies published between 2016 and 2021 met the final inclusion criteria. Overall, 16 articles (109 cases) were included in this study, among which fifteen (107 patients) were involved VNS, and one (2 patients) was involved DBS. After VNS implantation, seizures were reduced to ≥50% in 60 cases (56%), seizure free were found in 8 cases (7.5%). Only two DS patients received DBS treatment, and the initial outcomes of DBS implantation were unsatisfactory. The seizures significantly improved over time for both DBS patients after the addition of antiepileptic drugs.

Conclusion: More than half of the DS patients benefited from VNS, and VNS may be effective in the treatment of DS. However, it is important to note that VNS does not guarantee improvement of seizures, and there is a risk of infection and subsequent device failure. Although DBS is a safe and effective strategy for the treatment of refractory epilepsy, the role of DBS in DS needs further study, as the sample size was small. Thus far, there is no strong evidence for the role of DBS in DS.

Citing Articles

Norwegian population-based study of effectiveness of vagus nerve stimulation in patients with developmental and epileptic encephalopathies.

Kostov K, Kostov H, Larsson P, Henning O, Aaberg K, Egge A Epilepsia Open. 2024; 9(2):704-716.

PMID: 38318727 PMC: 10984305. DOI: 10.1002/epi4.12908.


Epilepsy Surgery for Cognitive Improvement in Epileptic Encephalopathy.

McLaren J, Kahle K, Richardson R, Chu C Neurosurg Clin N Am. 2023; 35(1):49-59.

PMID: 38000841 PMC: 11384968. DOI: 10.1016/j.nec.2023.08.002.


Two Perspectives on Dravet Syndrome: Viewpoints from the Clinician and the Caregiver.

Bluvstein J, Wenniger S Neurol Ther. 2023; 12(2):343-350.

PMID: 36795289 PMC: 10043082. DOI: 10.1007/s40120-023-00450-3.

References
1.
Rossignol E, Lortie A, Thomas T, Bouthiller A, Scavarda D, Mercier C . Vagus nerve stimulation in pediatric epileptic syndromes. Seizure. 2008; 18(1):34-7. DOI: 10.1016/j.seizure.2008.06.010. View

2.
Plosker G . Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome). CNS Drugs. 2012; 26(11):993-1001. DOI: 10.1007/s40263-012-0004-3. View

3.
Nickels K, Wirrell E . Stiripentol in the Management of Epilepsy. CNS Drugs. 2017; 31(5):405-416. DOI: 10.1007/s40263-017-0432-1. View

4.
Murphy P, Likhodii S, Nylen K, Burnham W . The antidepressant properties of the ketogenic diet. Biol Psychiatry. 2004; 56(12):981-3. DOI: 10.1016/j.biopsych.2004.09.019. View

5.
Caraballo R . Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia. 2011; 52 Suppl 2:79-82. DOI: 10.1111/j.1528-1167.2011.03009.x. View